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Background: Hyperbilirubinemia can lead to potentially irreversible bilirubin-induced neurotoxicity. Transcutaneous
bilirubin (TcB) determination has become a valuable aid in non invasive screening of neonatal jaundice.
The aim of this study is to compare the performance of three most widespread transcutaneous bilirubinometers on
a multiracial population of term and late pre-term neonates.
Methods: Bilirubin concentration was determined using traditional photometric determination and
transcutaneously with Bilicheck, BiliMed and JM-103, in random order.
Total serum bilirubin (TSB) was determined over a wide concentration range (15,8–0,7 mg/dl) with a mean of 9,5
mg/dl. Related TcB values using Bilicheck (TcB-BC), BiliMed (TcB-BM), and JM-103 (TcB-JM) are reported in Table 1.
Results: A multiracial population of 289 neonates was enrolled with a gestational age ranging from 35 to 41 weeks;
birth weight ranging from 1800to 4350 grams; hours of life ranging from 4 to 424. In the total study population
correlation analysis using Pearson coefficients showed good results for Bilicheck (r = 0.86) and JM-103 (r = 0.85) but
poor for BiliMed (r = 0,70). Similar results were found for the non-Caucasian neonates subgroup. Bilicheck and
JM-103 had a greater area under the curve than BiliMed when TSB =14 mg/dl was chosen as a threshold value
both for the total study population and the non-Caucasian subgroup.
Conclusions: Bilicheck and JM-103, but not BiliMed, are equally reliable screening tools for hyperbilirubinemia in
our multiracial neonatal population.Background
Transcutaneous bilirubin (TcB) determination has become
a valuable aid in avoiding significant neonatal hyperbiliru-
binemia [1] and has significantly reduced the number of
heel stick blood samplings and their complications [2].
Current technology analyses the light reflected by the skin
and the subcutaneous tissue providing a useful alternative
measurement for total serum bilirubin (TSB). Neonatal
skin colour and thickness represents important variables
in TcB measurements. Different devices have been
individually validated versus spectrophotometric or high
pressure liquid chromatography determination of TSB,
often on neonates with a single ethnic background [3].* Correspondence: raimondi@unina.it
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reproduction in any medium, provided the orTo provide useful clinical information, we compared
the performance of the three most widespread transcuta-
neous bilirubinometers on a multiracial population of
term and late pre-term neonates.
Methods
Infants born at the well baby nursery of the University
“Federico II” of Naples with gestational age over 35 weeks
were enrolled between January and December 2009. The
investigation protocol was approved by the local ethical
committee and parental consent was obtained.
Infants with Rh or ABO isoimmunisation, major con-
genital malformations, haemoglobinopathies or evidence
of liver disease were excluded from the study.
Infants with post-natal age from 4 to 75 hours were mea-
sured TSB by an experienced resident (SL) as ordered by
the attending clinician unaware of the study purpose.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Basic characteristic and clinical variables of
infants with hyperbilirubinemia
Mean birthweight (gr) 3060
range 1800-4350







Mean TSB (mg/dl) 9.5
range (15.8-0.7)
Mean TcB Bilicheck (mg/dl) 9.8
range (17.2-0.4)
Mean TcB Minolta JM103 (mg/dl) 9.8
range (18.8-0.1)
Mean TcB Bilimed (mg/dl) 10.4
range (17.5-2.9)
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centrifuged at 3000 rpm for five minutes and then read by
a direct spectrophotometer (GB13A, Bertocchi Elettrome-
dicali, Cremona, Italy). Spectrophotometry was used as a
reference as it is the technique used in daily routine and
has better agreement with high pressure liquid chromatog-
raphy (HPLC) than any other technique [4].
Within 20 minutes before TSB determination, TcB was
measured on the infant’s forehead, protected from direct
sunlight and avoiding areas with hair, bruises, nevi or
other skin anomalies.
We used three well known transcutaneous bilirubin-
ometers according to the manifacturer’s instructions.
Bilicheck (SpectRX, Norcross, GA) was calibrated using
a Bilical before each measurement, calculated averaging
five readings. The device scans the whole spectrum of
visible light and automatically subtracts the light
reflected by confounding factors like haemoglobin or
melanin. BiliMed (Medick, S.A. France) operates by ten
light emitting diodes that form a single beam when hit-
ting the newborn skin. A silicon diode captures the
reflected light and the internal software calculates the
highest intensity for every wavelength range. BiliMed
was used as recommended at 2 cm from the neonate’s
forehead. JM-103 (Draeger Medical Systems, Inc.,
Telford, PA) uses 2 wavelengths and a dual optical path
system; each measurement was calculated averaging five
readings.
All measurements were performed in the ambient
morning light of the nursery, in random order according
to a computer generated randomization table.
Data were analyzed using MedCalc software v.11
(MedCalc Software, Mariakerke, Belgium). Linear regres-
sion analysis, Pearson correlation coefficients, Bland-
Altman plots and receiver operating curve (ROC) were
performed.
Results
A total of 343 determinations obtained on 253 Caucasian
and 36 West African infants were included in the study.
The demographic characteristics are shown in Table 1.
TSB was determined over a wide concentration range
(15,8 – 0,7 mg/dl) with a mean of 9.5 mg/dl. Related
TcB values using Bilicheck (TcB-BC), BiliMed (TcB-BM),
and JM-103 (TcB-JM) are reported in Table 1. Figure 1A
shows the linear regression analysis for the three trans-
cutaneous bilirubinometers on the whole study popula-
tion. Pearson’s coefficients were almost equivalent for
BiliCheck (0.86) and JM-103 (0.85) but substantially
lower for BiliMed (0.70). Extrapolating non-Caucasian
infants, correlation coefficients were 0.92 for JM-103,
0.88 for BiliCheck and 0.74 for BiliMed (Figure 1B).
Error plots for the three devices are shown in Figure 2.
Bilicheck showed a lower trend to underestimate TSB;this was more evident for BiliMed which also was the
least accurate, while JM-103 had a tendency to
overestimate and a distribution of 98% of measurements
that was intermediate between Bilicheck and BiliMed.
Figure 3 reports ROC curves for the three transcutane-
ous bilirubinometers when TSB> 14 mg/dl was used as
cut-off, on the whole population (Figure 3A) and on the
non-Caucasian subgroup (Figure 3B). The areas under
the curve resulted 0.95 for Bilicheck, 0.75 for Bilimed
and 0.91 for JM-103 on the whole population; for the
non-Caucasian subgroup the areas under the curve were
0.98 for Bilicheck, 0.75 for Bilimed and 0.94 for JM-103.
Discussion
In a comparative evaluation of the three most common
transcutaneous bilirubinometers we showed that Bilicheck
and JM-103 but not BiliMed are reliable screening tools
for moderate neonatal hyperbilirubinemia. The latter de-
vice resulted inferior to Bilicheck in previous studies on
Caucasian populations [5,6]. We found that on non-
Caucasians BiliMed looses further ground to JM-103 and
Bilicheck, the two transcutaneous bilirubinometers with
the largest literature and broadest distribution. We also
provided the first direct comparison of Bilicheck and
JM-103 on a multiracial population as previous authors
investigated these technologies on Asian or Caucasian
infants [7-9].
In the present study, both JM-103 and Bilicheck
resulted equally accurate screening tools over the range
of concentrations tested, regardless of the skin pigmen-
tation. JM-103, in particular, represents an improvement
of a previous device. In the study of Robertson et al.










































r =  0.86
p< 0.0001
y = 0.8901 + 0.9326
r =  0.70
p< 0.0001
y = 3.7747 + 0.6943 x 
r =  0.85
p< 0.0001
y = 0.5642 + 1.0084 x 
Figure 1 A. Pearson’s correlation coefficients for the whole population. B. Pearson’s correlation coefficients for African population.
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by the skin color. In the present study, JM-103 had a
good performance on dark skinned infants, required no
disposables to calibrate and was quicker to operate than
Bilicheck.
Looking at the Bland Altman plots, the three
devices had a tendency to overestimation on higher
end of the tested concentration range. Although this
may be per se protective against the clinical damage
of hyperbilirubinemia, one would expect that newer
technologies should be more accurate therefore
expanding the concentration range where a TSB de-
termination can be spared. We acknowledge a limita-
tion of the study as we do not provide comparativedata on preterm infants. Previous studies have shown
that transcutaneous bilirubin evaluation can be use-
ful on this population which is at increased risk of
clinical damage as early as 24 weeks of gestational
age [10]. It will be interesting to compare data on
preterm infants since, as in the present study on late
preterm and term infants, devices using different
technologies may have variable performances. Clini-
cians need to be aware of these differences.
Conclusions
In our multiracial neonatal population Bilicheck and JM-
103, but not BiliMed, are equally reliable screening tools
for hyperbilirubinemia.













































































































































































Figure 2 A and 2B. Bland Altman plot for the whole population and for African neonates respectively. These graphs show the mean



































BiliCheck Bilimed JM 103 
AUC 0.95                0.75                     0.92
95% CI 0.92-0.97 0.7-0.79 0.88-0.95 
Difference between areas
BiliCheck/Bilimed 0.197 p = 0.001 
BiliCheck/JM 103  0.028 p = 0.511 
Bilimed/JM 103  0.169 p = 0.007 
Figure 3 ROC curves when TSB> 14 mg/dl was the outcome of choice for the three transcutaneous bilirubinometer (A: whole
population; B: African neonates). AUC and difference between areas are reported for whole population.
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